

Application No.: 10/582,006
Filing Date: June 7, 2006

REMARKS

Claim 1 has been amended, Claim 25 has been cancelled and new Claims 27 to 33 have been added. Accordingly, Claims 1-24 and 26-33 are presented for examination on the merits.

In the Office Action, the Examiner required restriction to one of the following groups of claims:

- 1) Group 1, Claims 1-24, drawn to dengue monoclonal antibodies;
- 2) Group 2, Claims 25, drawn to pFAV CMV-dhfr vector.

Applicants hereby elect Group 1, Claims 1-24 and 26-33 for examination, without traverse.


The Examiner also stated that Group 1 had claims directed to more than one species of the generic invention. Applicant elects the species of 5H2, without traverse. Claims 23 and 32 read on the elected species, while claims 1-22 and 26-31 are generic.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 7, 2006

By: 

Eric S. Furman
Registration No. 45,664
Attorney of Record
Customer No. 45,311
(619) 235-8550

5473772:060408/Jade